Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Potential Role of Inflammasome NLRP3 And IL-1B Gene Expression In COVID-19 Patients: Impact of Ferretin and D -Dimer.

NCT06080750 is registered in ClinicalTrials.gov with Assiut University as lead sponsor.

NCT NCT06080750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06080750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Potential Role of Inflammasome NLRP3 And IL-1B Gene Expression In COVID-19 Patients: Impact of Ferretin and D -Dimer.
Lead sponsor
Assiut University
Phase
Observational
Overall status
Unknown status
Start date
January 1, 2023
Completion date
January 1, 2025
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

inflammasome nlrp3 and il-1b gene expression in covid-19 patients